PCGF3-AS1: A Potential Drug Target and Biomarker (G100129917)

Target Name: PCGF3-AS1

NCBI ID: G100129917

PCGF3-AS1

Other Name(s): PCGF3 antisense RNA 1, transcript variant 1 | PCGF3 antisense RNA 1 | PCGF3 antisense RNA 1, transcript variant 2

PCGF3-AS1: A Potential Drug Target and Biomarker

PCGF3-AS1, also known as interleukin-3 receptor alpha chain subunit 3A, is a protein that is expressed in various tissues throughout the body. It is a key component of the interleukin-3 receptor alpha chain, which plays a crucial role in the regulation of immune and inflammatory responses. PCGF3-AS1 has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and inflammatory diseases.

The interleukin-3 receptor alpha chain is a protein that is composed of four subunits: alpha chain subunit 1 (ITG伪), alpha chain subunit 2 (ITG尾), alpha chain subunit 3 (ITG纬), and alpha chain subunit 4 (ITG未). These subunits form the alpha chain of the interleukin-3 receptor, which is a protein that is involved in the regulation of immune and inflammatory responses.

PCGF3-AS1 is a 24-kDa protein that is expressed in various tissues, including the skin, muscle, liver, and spleen. It is highly expressed in the liver, with lower levels found in the muscle and skin. PCGF3-AS1 is also expressed in various cell types, including immune cells, endothelial cells, and epithelial cells.

PCGF3-AS1 has been shown to play a role in the regulation of immune responses. It has been shown to enhance the production of natural killer cells (NK cells) in the liver, which are important for immune surveillance. PCGF3-AS1 has also been shown to regulate the production of pro-inflammatory cytokines, such as TNF-alpha and IL-12, in immune cells.

In addition to its role in immune regulation, PCGF3-AS1 has also been shown to be involved in the regulation of cell survival and angiogenesis. It has been shown to promote the growth and survival of various cell types, including cancer cells. PCGF3-AS1 has also been shown to play a role in the regulation of cell migration and the formation of blood vessels.

As a potential drug target, PCGF3-AS1 has been shown to be involved in the regulation of various diseases, including cancer, autoimmune disorders, and inflammatory diseases. For example, PCGF3-AS1 has been shown to promote the growth and survival of cancer cells, and to inhibit the production of pro-inflammatory cytokines in cancer cells. It has also been shown to be involved in the regulation of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.

In addition to its potential as a drug target, PCGF3-AS1 has also been identified as a potential biomarker for various diseases. For example, PCGF3-AS1 has been shown to be involved in the regulation of inflammation, and to be a potential indicator of disease severity in various inflammatory disorders. It has also been shown to be involved in the regulation of cell survival and angiogenesis, and to be a potential biomarker for various diseases, including cancer.

Overall, PCGF3-AS1 is a protein that has been shown to play a role in the regulation of various diseases, including cancer, autoimmune disorders, and inflammatory diseases. As a potential drug target and biomarker, PCGF3-AS1 has the potential to be a valuable tool for the development of new treatments for these diseases. Further research is needed to fully understand the role of PCGF3-AS1 in the regulation of immune and inflammatory responses, and to develop effective treatments based on this protein.

Protein Name: PCGF3 Antisense RNA 1

The "PCGF3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCGF3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets